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To investigate localised prostate cancer (PCa) treated with or without neoadjuvant androgen 
deprivation therapy (neoADT) prior to robot-assisted laparoscopic prostatectomy (RALP), and 
the impact of coronavirus-19 disease (Covid-19) treatment disruption, on clinico-pathologic 
outcomes. 
 
Patients and methods 
 
Data was retrospectively collected from 124 consecutive patients treated with RALP between 
November 2019 to September 2020. 62 patients were treated before March 13th (historic 
cohort) and 62 afterwards (covid cohort). 37 patients in covid cohort additionally received 
neoADT (mean duration of 3 months) consisting of Bicalutamide 150mg OD for 4 weeks, with 




Statistical analysis found no difference to peri-operative measures and length of stay for 
patients treated with or without neoADT. Patients with delayed surgical treatment offered 
neoADT showed a trend towards a reduction in positive surgical margins (P = 0.134), N1 
disease (P = 0.424) and pathological down-staging (50% patients with pT2 disease). Patients 




Our study demonstrated that a 3-month duration of neoADT prior to RALP may improve 
pathological outcomes but this timeframe is inadequate to influence detectable PSA levels. 
Covid-19-related treatment delays led to significantly increased detectable PSA levels. 
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Amidst the current coronavirus-19 (Covid-19) pandemic, prostate cancer (PCa) patients have 
experienced postponements to their curative surgical treatments on a global scale(1). One of 
the most significant effects due to delay in surgery is psychological morbidity(2,3). Little is 
known about the oncological outcomes, particularly in a contemporary cohort of high risk 
locally advanced prostate cancers. The current management strategies of PCa patients are 
mostly driven by findings from studies conducted prior to the Covid-19 pandemic. Many 
centres have delayed their prostatectomy treatment, whilst a few centres have opted to 
continue performing surgeries during this time. To address the delay, some institutions have 
trialled neoadjuvant androgen deprivation therapy (neoADT) prior to robot-assisted 
laparoscopic prostatectomy (RALP)(4,5), whilst others have opted for watchful waiting(3). It 
is not surprising for trialling neoADT as the treatment modality of choice, given that previous 
studies assessing neoADT have shown promise by reduction of post-surgical margins, but 
without any benefit on long term patient and surgical outcomes(6,7). 
 
As of present, there is a real lack of a strong evidence base for management of PCa patients 
during Covid-19 as informed by the analysis of patient outcomes during the initial months of 
the pandemic itself. We investigated the impact of the Covid-19 pandemic on patients 
undergoing radical surgical treatment at our practice and examined if the delay negatively 
impacted on surgical and patient outcomes. In particular, our primary objective was to 
compare the clinic-pathologic outcomes of localised PCa treated with or without neoADT 
prior to RALP. 
 
Materials and Methods 
 
Patient Selection and Study Design 
124 consecutive men, diagnosed with localised PCa and treated with RALP, were selected 
from our regional centre, the Queen Elizabeth University Hospital (QEUH), Glasgow, UK. 
Patients were divided into 2 cohorts. 62/124 men treated prior to Covid-19 (November 2019 
– March 2020) formed the historic cohort. The remaining 62/124 patients treated during 
Covid-19 (March 2020 – September 2020) formed the covid cohort. Written informed consent 
was obtained from patients for their anonymized information to be published in this article. 
Appropriate ethical approval was obtained as part of the NHS Greater Glasgow & Clyde 
(GG&C) Audit programme and patient-related data were securely kept in accordance with 
The Data Protection Act 1998 and local National Health Service (NHS) Trust policy. 
 
Treatment & Follow-up 
All 62 men from historic cohort and 25 patients from covid cohort received RALP alone. The 
remaining 37 patients in covid cohort received neoADT prior to RALP. 
 
More specifically, neoADT initiated with 4 weeks of Bicalutamide 150mg OD, an anti-
androgen. After week 1, all patients transitioned to Leuprolide 3.75mg monthly subcutaneous 
injections, a luteinizing hormone release hormone agonist (LHRHa), with Bicalutamide 
continuing on for a further 3-weeks alongside. NeoADT continued up until the surgical date. 
NeoADT duration was 3-months (mean of 89 days). 
All patients were followed up until 6-weeks after RALP, with assessment of serum prostate-
specific antigen (PSA) level, acting as our primary endpoint. PSA measurements ≥0.1ng/ml 
were defined as “detectable PSA”. 
 
Data Collection 
Patients’ medical records were reviewed to extract clinical, surgical, pathological and 
biochemical data until September 2020, in a retrospective manner. 
 
We abstracted patient-level variables including age, BMI, duration of waiting list occupancy 
and surgical school attendance. Disease-related parameters includes clinical and pathological 
tumor stage (cT and pT, respectively), post-operative surgical margin (PSM) status, lymph 
node (LN) status, biopsy gleason grade and PSA level, measured pre-and-post-operatively. cT 
and pT were determined according to the eighth edition of the TNM Classification of 
Malignant Tumours(8). Tumor grade of the diagnostic prostate biopsy material and surgical 
specimens was determined according to Gleason scoring system 2014 guidelines by 
International Society of Urological Pathology(9). 
 
Statistical analysis 
Initial patient characteristics including age, BMI, cT stage, biopsy Gleason grade, pre-
operative PSA level acted as co-variables, whilst neoADT provision or cohort status, 
accounting for treatment delay, acting as response variables. Differences in continuous and 
categorical variables were examined using Independent-Samples T Test and Chi-square test, 
respectively. Mean, median, range and standard deviations were generated for continuous 
variables, and frequencies and proportions were generated for categorical variables. 
 
All data analysis was performed using Statistical Package for the Social Sciences (SPSS) Version 






Clinic-pathologic characteristics of historic and covid cohorts were comparable (Table 1) with 
similar age, clinical tumour (cT) stage, tumour grade (Gleason score) and presenting serum 
PSA levels. 
 
Among patients within the covid cohort, patients who received neoADT had a significantly 
higher tumour grade (median of 2.0 and a range of 3)(P = 0.016). Similarly, the patients 
receiving neoADT within the covid cohort, had a higher cT stage, with 0% of patients with cT1 
disease compared to 12.5% in RALP alone group (P = 0.036) and with an increased likelihood 
of high-risk disease according to the Di Amico Classification (83.8% vs 70.8%, P = 0.230) (Table 
2). 
 
The only difference amongst baseline characteristics between the groups is the length of wait 
till surgery. Compared to historic cohort, covid cohort patients experienced a significantly 
lengthier wait till surgery (16.34 weeks vs 5.03; P < 0.0001), shown in Table 2. 
 
Peri-operative and immediate post-operative period 
Wait till surgery and neoADT status had no impact on peri-operative and immediate post-
operative measures, in terms of volume of blood loss, operating times and length of hospital 
stay (LOS)(Table 3). All groups within both cohorts recorded a median LOS of 3 days. Within 
the covid cohort, there is a trend of neoADT in reducing operation times compared to RALP 
alone therapy (135.57 minutes vs 165.72, P = 0.814) (Table 3). 
 
Pathological indicators of prognosis at the time of RALP 
Pathological findings, including post-operative surgical margins (PSMs), pT-stage and LN 
status (pN), were compared amongst both cohorts (Table 4). 
 
For patients within covid cohort, neoADT demonstrated a trend towards increased negative 
surgical margins (82.4% vs 62.5%, P = 0.134) at each margin location: apical (91.2% vs 81.3%), 
basal (94.1% vs 87.5%) and circumferential (91.2% vs 87.5%). Similarly, within the covid 
cohort, neoADT demonstrates a trend towards pathological downstaging (50% patients with 
pT2 disease) compared to RALP alone (50% patients with pT3a disease) and a reduction in 
positive pN (20% vs 33.3% N1 disease; P = 0.424). 
 
Our pN results demonstrates a trend of increased N1 disease in covid cohort compared to 
historic cohort (23.5% vs 7.7%, P = 0.110) coupled with a significantly elevated risk of sampled 
LNs being positive (P = 0.043). 
 
Detectable PSA following RALP 
PSA levels, measured 6-weeks after RALP, did not show any statistical difference amongst 
patients given neoADT or RALP alone, within the covid cohort. Between the covid and historic 
cohorts, a significantly lower rate of detectable PSA values were found in historic cohort (3.3% 
versus 21.7%, P = 0.007) (Table 5). 
 
Surgical school attendance and implications 
The impact of Covid-19 pandemic on surgical school parameters were explored in Table 6. 
There was a significantly higher level of surgical school attendance amongst men treated in 





Peri-operative and immediate post-operative period 
Our findings remain consistent with literature, re-enforcing a lack of improvement in peri-
operative and immediate post-operative measures after neoADT(10). In line with a previous 
study, we explored this measure using surrogates of blood loss, operative time and LOS(10). 
The trend of neoADT in reducing operation times compared to RALP alone therapy within the 
covid cohort (135.57 minutes vs 165.72, P = 0.814) is confounded by inter-surgeon variability, 
given that at our unit, patients considered for RALP are referred to specific surgeons based 
on the baseline level of risk. Moreover, patients considered for neoADT at our unit are likely 
to have a higher baseline risk. 
 
 
Pathological indicators of prognosis at the time of RALP 
The overwhelming evidence of an improvement of pathological outcomes with neoADT 
(7,11–13) is somewhat replicated in our findings. 
 
With a trend of neoADT being prescribed to the more advanced high-risk patients at our unit, 
often with larger tumour sizes, witnessing increased negative rates of PSM status is very 
promising, advocating the use of neoADT for PCa patients. However, considerably shrunken 
tumours(14) make it trickier to accurately determine the tumour at the inked margins(15). 
The scope for a reduction of nodal metastasis with neoADT amongst covid cohort patients is 
explained by the systemic action of ADT, readily acting on and transforming micro-metastasis 
into node-negative (N0) disease (11), as well as reducing the potential for metastasis in the 
first instance(16).  
 
Initial observations suggest that the prolonged waiting list occupancy due to Covid-19 has not 
led to worse pathological outcomes in terms of PSMs or pT stage. Our pN findings suggest 
that it may be likely that the delay prior to RALP, has led to increased likelihood of disease 
progression and LN metastasis for patients in the covid cohort. 
 
Detectable PSA following RALP 
Our study did not identify a reduction in detectable PSA levels as a result of neoADT directly, 
nor with a 3-month duration of neoADT. A longer duration of neoADT beyond 3 
months(12,17), may show more conclusive results. Another study has demonstrated that 8 
months duration of neoADT prior to RALP leads to a significant decrease in PSA failure 
rates(18). 
 
Our findings of a significant reduction of detectable 6-week PSA levels in our historical cohort 
compared to covid cohort may be attributable to the Covid-19 treatment delays. This has led 
to the increased chance of detectable PSA levels amongst patients within covid cohort. 
Moreover, the increased likelihood of prostate-confined disease at RALP in historic cohort, 
due to shorter waiting times, may explain the significantly reduced detectable PSA levels 
within this cohort. 
 
Surgical school attendance and implications 
Shortly after an operation is planned, patients are invited to attend a single session of surgical 
school. This acts as part of enhanced recovery after surgery (ERAS) scheme, to optimize 
patient outcomes from their surgery by explanation of what to expect after surgery(19). 
Moreover, patients are primed to be more involved in their care, to increase their levels of 
motivation to stay fit to meet the physical demands of their operation. 
 
The variation in surgical school attendance rates amongst both cohorts stems from multiple 
attributable factors linked to the Covid-19 pandemic, including the patients’ fears of Covid-
19 infection from hospital attendance and increased levels of isolation amongst cancer 
patients being more at-risk of poorer outcomes from Covid-19 disease(1). Without a 
postponement to RALP treatment prior to the Covid-19 pandemic, historic cohort patients 
experienced a significantly shorter timeframe post-surgical school until their operation. 
 
During Covid-19, surgical school has shown promise in terms of increased patient outcomes 
and health care cost savings(19,20). Although, in our study, given that LOS and peri-operative 
measures were indifferent amongst both cohorts, makes the true impact of surgical school 
attendance questionable. Further studies are needed, to confirm our preliminary data and to 
gauge the long-term patient outcomes, including rates of re-admission. Ideally questionnaire-
based studies will be valuable assets to explore patients’ peri-operative experience, 
depending on their surgical school attendance status. 
 
Main findings of this study 
The provision of neoADT shows a trend of an improvement in pathological outcomes in terms 
of PSMs, pT and N1 disease. There was no impact on perioperative care and LOS despite a 
long wait with or without neoADT. 
 
Limitations 
A longer duration of follow-up will enable assessment of whether patients on neoADT have 
higher rates of biochemical failure after initial undetectable PSA levels. In our institute, RALP 





During the Covid-19 pandemic, patients experienced a significantly lengthier waiting list 
occupancy, higher rates of surgical school non-attendance and a delay to their surgical 
treatment. The provision of neoADT for patients during the delay yielded no improvements 
to peri-operative measures and LOS, when compared to patients not experiencing delays to 
treatment prior to the Covid-19 pandemic. Given the trend of patients with delayed 
treatment experiencing increased pN disease, additional neoDT for a subgroup of patients 
within the covid cohort demonstrated a trend towards pathological downstaging (pT), 
reduced PSMs and node positive disease. Treatment delays led to significant rates of 
detectable PSA. The 3-month neoADT duration in this study was inadequate to significantly 
influence post-operative detectable PSA levels amongst patients in the covid cohort. This data 
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Table 1 – Baseline characteristics of patients within the covid and historic cohorts.  
 
 









Mean Biopsy Gleason 
Group  
Mean pre-operative 
PSA (ng/ml)  
 







Mean duration of 
waiting list occupancy 
(weeks) 
 
62.79 (SD 6.01) 




2.30 (SD 0.92) 
 










16.34 (SD 7.74) 
 
64.50 (SD 6.38) 




2.35 (SD 0.93) 
 





























†cT stage: results from 12 patients within the covid cohort have been omitted from this table due to the unavailability 
of corresponding pathological T stage results 
BMI, body mass index; cT, clinical T stage; PSA, prostate specific antigen 
Standard deviations (SD) are shown within brackets 
Proportions (in %) are shown in brackets 
Results with statistical significance are denoted with (*) 
Table 2 – Baseline characteristics of patients within the covid cohort, who received neoadjuvant 
androgen deprivation therapy (neoADT) prior to robot-assisted laparoscopic prostatectomy (RALP) 
or RALP treatment alone.  
Covid Cohort 




























62.16 (SD 6.43) 




2.53 (SD 0.85) 
 















63.72 (SD 5.48) 




1.96 (SD 0.94) 
 

























































Mean duration of 














†cT stage:  results from 3 patients in the neoADT group and 9 patients from the RALP alone group have been omitted 
from this table due to the unavailability of corresponding pathological T stage results 
°Di Amico Risk Group: 1 patient in the RALP alone group was not included in the table due to the unavailability of the 
clinical T stage result 
NeoADT, neoadjuvant androgen deprivation therapy; RALP, robot-assisted laparoscopic prostatectomy; BMI, body mass 
index; cT, clinical T stage; PSA, prostate specific antigen 
Standard deviations (SD) are shown within brackets 
Proportions (in %) are shown in brackets 
Results with statistical significance are denoted with (*) 
Table 3 – Comparison of peri-operative and immediate post-operative parameters amongst patients 
within the covid and historic cohorts.  
 Covid cohort Both cohorts 
Variable Neoadjuvant 
















































































NeoADT, neoadjuvant androgen deprivation therapy; RALP, robot-assisted laparoscopic prostatectomy 










Table 4 - Comparison of pathological indicators of prognosis amongst patients within the covid and 
historic cohorts.  
 Covid cohort Both cohorts 
Variable Neoadjuvant 
























































































































































































































































































































































































































































† Surgical margins: due to the unavailability of pathological data within the covid cohort, results from 3 patients in the 
neoADT group and 9 patients from the RALP alone group are not present in the table 
°pT stage: due to the unavailability of pathological data, results from 9 patients in covid group are not present in the 
table 
ˆpN status: due to unavailability of pathological data in the covid group, results from 12 patients treated with neoADT 
and 16 patients treated with RALP alone, are not present in the table 
NeoADT, neoadjuvant androgen deprivation therapy; RALP, robot-assisted laparoscopic prostatectomy 
Standard deviations (SD) are shown within brackets 
Proportions (in %) are shown in brackets 
Results with statistical significance are denoted with (*) 
Table 5 – Comparison of post-operative PSA levels amongst patients within the covid and historic 
cohorts.  
 Covid cohort Both cohorts 
Variable Neoadjuvant 


































































































































† 6-week PSA status: due to the unavailability of data, results from 39 patients in covid cohort and 1 patient from the 





























NeoADT, neoadjuvant androgen deprivation therapy; RALP, robot-assisted laparoscopic prostatectomy 
Proportions (in %) are shown in brackets 
Results with statistical significance are denoted with (*) 




 Covid cohort Both cohorts 
Variable Neoadjuvant 














































































































































NeoADT, neoadjuvant androgen deprivation therapy; RALP, robot-assisted laparoscopic prostatectomy 
Proportions (in %) are shown in brackets 
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